Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1804 1
1950 1
1951 1
1953 1
1954 1
1956 3
1957 2
1958 2
1959 1
1960 1
1962 5
1963 2
1965 3
1966 2
1967 6
1968 7
1969 5
1970 1
1971 5
1972 8
1973 3
1974 5
1975 4
1976 3
1977 7
1978 2
1979 7
1980 4
1981 6
1982 10
1983 8
1984 14
1985 12
1986 13
1987 15
1988 7
1989 15
1990 9
1991 12
1992 13
1993 13
1994 9
1995 19
1996 8
1997 14
1998 12
1999 10
2000 12
2001 16
2002 14
2003 16
2004 12
2005 22
2006 22
2007 22
2008 23
2009 34
2010 23
2011 27
2012 32
2013 41
2014 25
2015 38
2016 37
2017 25
2018 30
2019 24
2020 32
2021 27
2022 39
2023 27
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

875 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK. Daver N, et al. Among authors: bradley t. J Clin Oncol. 2022 Dec 10;40(35):4048-4059. doi: 10.1200/JCO.22.00602. Epub 2022 Jul 18. J Clin Oncol. 2022. PMID: 35849791 Free PMC article. Clinical Trial.
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Sallman DA, Al Malki MM, Asch AS, Wang ES, Jurcic JG, Bradley TJ, Flinn IW, Pollyea DA, Kambhampati S, Tanaka TN, Zeidner JF, Garcia-Manero G, Jeyakumar D, Komrokji R, Lancet J, Kantarjian HM, Gu L, Zhang Y, Tan A, Chao M, O'Hear C, Ramsingh G, Lal I, Vyas P, Daver NG. Sallman DA, et al. Among authors: bradley tj. J Clin Oncol. 2023 May 20;41(15):2815-2826. doi: 10.1200/JCO.22.01794. Epub 2023 Mar 8. J Clin Oncol. 2023. PMID: 36888930 Clinical Trial.
Net-zero emissions energy systems.
Davis SJ, Lewis NS, Shaner M, Aggarwal S, Arent D, Azevedo IL, Benson SM, Bradley T, Brouwer J, Chiang YM, Clack CTM, Cohen A, Doig S, Edmonds J, Fennell P, Field CB, Hannegan B, Hodge BM, Hoffert MI, Ingersoll E, Jaramillo P, Lackner KS, Mach KJ, Mastrandrea M, Ogden J, Peterson PF, Sanchez DL, Sperling D, Stagner J, Trancik JE, Yang CJ, Caldeira K. Davis SJ, et al. Among authors: bradley t. Science. 2018 Jun 29;360(6396):eaas9793. doi: 10.1126/science.aas9793. Science. 2018. PMID: 29954954 Free article. Review.
Nucleoporins in cardiovascular disease.
Burdine RD, Preston CC, Leonard RJ, Bradley TA, Faustino RS. Burdine RD, et al. Among authors: bradley ta. J Mol Cell Cardiol. 2020 Apr;141:43-52. doi: 10.1016/j.yjmcc.2020.02.010. Epub 2020 Mar 21. J Mol Cell Cardiol. 2020. PMID: 32209327 Free PMC article. Review.
Sleep apnoea and heart failure.
Lévy P, Naughton MT, Tamisier R, Cowie MR, Bradley TD. Lévy P, et al. Among authors: bradley td. Eur Respir J. 2022 May 12;59(5):2101640. doi: 10.1183/13993003.01640-2021. Print 2022 May. Eur Respir J. 2022. PMID: 34949696 Free article.
Single-Cell Transcriptomics of Mtb/HIV Co-Infection.
Kulkarni S, Endsley JJ, Lai Z, Bradley T, Sharan R. Kulkarni S, et al. Among authors: bradley t. Cells. 2023 Sep 17;12(18):2295. doi: 10.3390/cells12182295. Cells. 2023. PMID: 37759517 Free PMC article. Review.
Servo-Ventilation Therapy for Sleep-Disordered Breathing.
Somers V, Arzt M, Bradley TD, Randerath W, Tamisier R, Won C. Somers V, et al. Among authors: bradley td. Chest. 2018 Jun;153(6):1501-1502. doi: 10.1016/j.chest.2018.03.052. Chest. 2018. PMID: 29884256 Review.
Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.
Williams WB, Meyerhoff RR, Edwards RJ, Li H, Manne K, Nicely NI, Henderson R, Zhou Y, Janowska K, Mansouri K, Gobeil S, Evangelous T, Hora B, Berry M, Abuahmad AY, Sprenz J, Deyton M, Stalls V, Kopp M, Hsu AL, Borgnia MJ, Stewart-Jones GBE, Lee MS, Bronkema N, Moody MA, Wiehe K, Bradley T, Alam SM, Parks RJ, Foulger A, Oguin T, Sempowski GD, Bonsignori M, LaBranche CC, Montefiori DC, Seaman M, Santra S, Perfect J, Francica JR, Lynn GM, Aussedat B, Walkowicz WE, Laga R, Kelsoe G, Saunders KO, Fera D, Kwong PD, Seder RA, Bartesaghi A, Shaw GM, Acharya P, Haynes BF. Williams WB, et al. Among authors: bradley t. Cell. 2021 May 27;184(11):2955-2972.e25. doi: 10.1016/j.cell.2021.04.042. Epub 2021 May 20. Cell. 2021. PMID: 34019795 Free PMC article.
The SERVE-HF Trial.
Bradley TD, Floras JS; ADVENT-HF Investigators. Bradley TD, et al. Can Respir J. 2015 Nov-Dec;22(6):313. doi: 10.1155/2015/751615. Epub 2015 Oct 16. Can Respir J. 2015. PMID: 26474274 Free PMC article. No abstract available.
875 results